Pilot study of GSK-3 drug tested in AD
February 13, 2013…A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2013;33:205-215). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…